![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
BK Yamamoto, JF Nash and GA Gudelsky
Department of Psychiatry, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA.
The effects of the amphetamine analog, 3,4- methylenedioxymethamphetamine (MDMA) were compared to the effects of d- amphetamine on the in vivo release of dopamine and gamma-aminobutyric acid (GABA) in the striatum and substantia nigra. The brain region- dependent role of the 5-HT2 receptors in the striatum and substantia nigra in regulating MDMA-induced dopamine and GABA release also was studied. Changes in the extracellular concentration of dopamine, 5-HT and GABA were measured simultaneously in the awake rat by in vivo microdialysis. The increase in striatal dopamine produced by systemic administration of MDMA was attenuated by infusion of TTX into the striatum. Infusion of the 5-HT2A/2C antagonist ritanserin into the striatum or the ipsilateral substantia nigra also significantly attenuated MDMA-induced dopamine release in the striatum. At the doses used in this study, MDMA but not d-amphetamine increased the extracellular concentrations of 5-HT and decreased GABA efflux in the substantia nigra. The ability of MDMA to decrease nigral GABA efflux also was blocked by the local infusion of ritanserin into either the substantia nigra or the striatum. Overall, these data provide evidence that MDMA increases dopamine release partly through an impulse-mediated mechanism. Furthermore, this increase in striatal dopamine efflux produced by MDMA is regulated, in part, by 5-HT2A/2C receptors in the striatum and the substantia nigra and ultimately by GABAergic input into the substantia nigra.
This article has been cited by other articles:
|
|
 |
|
  N. Easton and C. A. Marsden Ecstasy: Are animal data consistent between species and can they translate to humans? J Psychopharmacol, March 1, 2006; 20(2): 194 - 210. [Abstract] [PDF]
|
|
|
|
|
|
B. Goni-Allo, M. Ramos, I. Herv'as, B. Lasheras, and N. Aguirre Studies on striatal neurotoxicity caused by the 3,4-methylenedioxymethamphetamine/ malonate combination: implications for serotonin/dopamine interactions J Psychopharmacol, March 1, 2006; 20(2): 245 - 256. [Abstract] [PDF]
|
|
|
|
 |
|
 A. R. Green, A. O. Mechan, J. M. Elliott, E. O'Shea, and M. I. Colado The Pharmacology and Clinical Pharmacology of 3,4-Methylenedioxymethamphetamine (MDMA, "Ecstasy") Pharmacol. Rev., September 1, 2003; 55(3): 463 - 508. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. G. Bankson and K. A. Cunningham 3,4-Methylenedioxymethamphetamine (MDMA) as a Unique Model of Serotonin Receptor Function and Serotonin-Dopamine Interactions J. Pharmacol. Exp. Ther., June 1, 2001; 297(3): 846 - 852. [Abstract] [Full Text]
|
|
|
|
|
|
A. C. McCreary, M. G. Bankson, and K. A. Cunningham Pharmacological Studies of the Acute and Chronic Effects of (+)-3,4-Methylenedioxymethamphetamine on Locomotor Activity: Role of 5-Hydroxytryptamine1A and 5-Hydroxytryptamine1B/1D Receptors J. Pharmacol. Exp. Ther., September 1, 1999; 290(3): 965 - 973. [Abstract] [Full Text]
|
|
|
|
 |
|
 E. D. Abercrombie and P. DeBoer Substantia Nigra D1 Receptors and Stimulation of Striatal Cholinergic Interneurons by Dopamine: A Proposed Circuit Mechanism J. Neurosci., November 1, 1997; 17(21): 8498 - 8505. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. A. Barone and K. M. Shermock JR Designer Drugs of Abuse Journal of Pharmacy Practice, August 1, 1997; 10(4): 292 - 300. [Abstract] [PDF]
|
|
 |
 |
 |
|
 |
 |
 |
